CClinicalTrials.gg
CompletedNCT00274508Updated Dec 1, 2023

Effect of Tiotropium (Spiriva) on Exercise Tolerance in COPD Patients

A Phase 3 interventional study of tiotropium bromide in Pulmonary Disease, Chronic Obstructive, sponsored by Boehringer Ingelheim. Completed at 28 sites in 4 countries. Open to participants aged 40 Years to 75 Years. Per ClinicalTrials.gov, last updated 2023-12-01.

Sponsored by Boehringer Ingelheim · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Registered 5 years 2 months after the study started (first participant enrolled Oct 2000, registered Jan 2006).
Phase
Phase 3
Study type
Interventional
Enrollment
261
Allocation
Randomized
Ages
40 Years to 75 Years
Sex
All
01

Study summary

To investigate whether tiotropium (Spiriva) improves exercise endurance in patients with COPD

02

Conditions studied

  • Pulmonary Disease, Chronic Obstructive
03

In context

Pulmonary Disease, Chronic Obstructive

4,131 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 697 are open to participants now.

This study's enrollment of 261 is above the median of 70 across 2,926 interventional studies indexed under Pulmonary Disease, Chronic Obstructive.

Browse Pulmonary Disease, Chronic Obstructive studies →

Lead sponsor

Boehringer Ingelheim is the lead sponsor of 2,245 studies on the registry; 58 are open to participants now.

Of its 162 completed or terminated interventional studies of FDA-regulated products, 116 (72%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
40 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

Male or female patients with a clinical diagnosis of Chronic Obstructive Pulmonary Disease (COPD) based on American Thoracic Society (ATS) guidelines with:

  • Relatively stable, moderate to severe airway obstruction with an Forced Expiratory Volume in One Second (FEV1) less than or equal to 65% of predicted normal (determined at Visit 1).
  • Presence of lung hyperinflation as demonstrated by Functional Residual Capacity determined by body plethysmography (TGV(FRC)) greater than or equal to 120% of predicted normal (determined at Visit 1).
  • Age greater or equal to 40 years and less than or equal to 75 years.
  • A cigarette smoking history of more than ten pack-years. A pack-year was defined as the equivalent of smoking one pack of cigarettes per day for a year.
  • Able to perform all specified procedures and able to maintain all necessary records during the study period as required in the protocol.
  • Able to inhale the trial medication from the HandiHaler device.

Exclusion criteria

Exclusion criteria:

  • Patients with a significant disease other than COPD. A significant disease was defined as a disease which, in the opinion of the investigator, may have put the patient at risk because of participation in the trial or may have influenced the results of the trial or the patient's ability to participate in the trial.
  • Patients with clinically significant abnormal baseline hematology, blood chemistry or urinalysis. If the abnormality defined a disease listed as an exclusion criterion, the patient was excluded.
  • Patients with Serum Glutamic Oxaloacetic Transaminase (SGOT) ≥1.5 x ULN (upper limit of normal range), Serum Glutamic Pyruvic Transaminase (SGPT) ≥1.5 x ULN bilirubin ≥1.5 x ULN or creatinine ≥1.5 x ULN were excluded regardless of the clinical condition.
  • Patients with a recent history (i.e., 1 year or less) of myocardial infarction.
  • Patients with a recent history (i.e., 3 years or less) of heart failure, pulmonary edema, or patients with cardiac arrhythmia (with or without symptoms) or any contraindication to exercise.
  • Patients requiring the regular use of daytime oxygen therapy.
  • Patients with known active tuberculosis.
  • Patients with a history of cancer within the last 5 years. Patients with treated basal cell carcinoma were eligible.
  • Patients with a history of life-threatening pulmonary obstruction, or a history of cystic fibrosis or bronchiectasis.
  • Patients who had undergone thoracotomy with pulmonary resection. Patients with a history of thoracotomy for other reasons were evaluated as per the first exclusion criterion (i.e., significant disease other than COPD).
  • Patients with an upper respiratory tract infection in the 6 weeks prior to the Screening Visit (Visit 1) or during the run-in period.
  • Further exclusion criteria apply.
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double
Enrollment
261 participants (actual)

Interventions

  • Drugtiotropium bromide
06

What researchers measure

Primary outcomes

  1. Endurance time during a constant work rate exercise test to symptom limitation

    Time frame: 2 hours and 15 minutes after trial medication administration on Day 42

Secondary outcomes

  1. Constant work rate exercise test to symptom limitation

    Time frame: 8 hours post-dose after 6 weeks of treatment

  2. Breathing discomfort during constant work rate exercise test as measured by the modified Borg Scale

    Time frame: 6 weeks

  3. Dynamic lung hyperinflation during exercise as determined by IRVdyn (IC minus VT) and EELVdyn (TLC)

    Time frame: 6 weeks

  4. Evaluation of VE and VEcap during exercise (selected centers)

    Time frame: 6 weeks

  5. Evaluation of static lung hyperinflation as measured by RV/TLC and by TGV(FRC)/TLC

    Time frame: 6 weeks

  6. Evaluation of TAC (TAV = TLC(BOX)-VA(IG))

    Time frame: 6 weeks

  7. Evaluation of slow vital capacity (SVC)

    Time frame: 6 weeks

  8. Evaluation of maximal expiratory flow rates and volumes FEV1, FVC, FEF25-75%, FEF50%, FEF75%, SVC

    Time frame: 6 weeks

  9. Evaluation of TGV, Raw, SGaw and RV

    Time frame: 6 weeks

  10. Evaluation of SaO2, VO2, VCO2, Ti, Te, VE, VT, breathing frequency (f) during constant work rate exercise test

    Time frame: 6 weeks

  11. Physician's Global Assessment

    Time frame: 6 weeks

  12. Assessement of Pulse/heart rate and blood pressure in conjunction with spirometry and exercise

    Time frame: 6 weeks

  13. Changes in Physical examination and ECG

    Time frame: 6 weeks

  14. Occurrence of Adverse Events

    Time frame: 6 weeks

07

Study locations

28 sites
  • St. Elizabeth's Medical Center of Boston
    Boston, Massachusetts, United States
  • Mayo Clinic
    Rochester, Minnesota, United States
  • St. Thomas Health Services
    Nashville, Tennessee, United States
  • Presbyterian Hospital of Dallas
    Dallas, Texas, United States
  • Phase I Unit
    Randwick, New South Wales, Australia
  • Immunology Department
    Westmead, New South Wales, Australia
  • Department of Respiratory Medicine
    Daw Park, South Australia, Australia
  • The Queen Elizabeth Hospital
    Woodville, South Australia, Australia
  • Department of Respiratory Medicine
    Heidelberg, Victoria, Australia
  • Respiratory Research
    Calgary, Alberta, Canada
  • University of Alberta
    Edmonton, Alberta, Canada
  • Respiratory Clinic
    Vancouver, British Columbia, Canada
  • Boehringer Ingelheim Investigational Site
    Halifax, Nova Scotia, Canada
  • Cardio Repiratory
    Hamilton, Ontario, Canada
  • Kingston General Hospital
    Kingston, Ontario, Canada
  • 1053 Carling Avenue
    Ottawa, Ontario, Canada
  • Department of Respiratory Medicine
    Toronto, Ontario, Canada
  • University Health Network - Toronto General Hospital
    Toronto, Ontario, Canada
  • Montreal Chest Institute - McGill University Health Centre
    Montreal, Quebec, Canada
  • Pulmonary Function Lab
    Montreal, Quebec, Canada
  • Hopital Laval
    Ste-Foy, Quebec, Canada
  • Boehringer Ingelheim Investigational Site
    Saskatoon, Saskatchewan, Canada
  • Pneumologisches Forschungsinstitut GmbH am Krankenhaus
    Hamburg, Germany
  • Fraunhofer-Institut für Toxikologie und
    Hannover, Germany
  • Universitätsklinikum Schleswig-Holstein
    Kiel, Germany
  • Klinikum der Universität zu Köln
    Köln, Germany
  • Neurologische Klinik der Otto-von-Guericke-Universität
    Magdeburg, Germany
  • Boehringer Ingelheim Investigational Site
    München, Germany
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Dec 1, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00274508
Lead sponsor
Boehringer Ingelheim
Responsible party
Sponsor
First posted
Jan 11, 2006
Start date
Oct 10, 2000
Primary completion
Jan 7, 2003
Last update
Dec 1, 2023

Study contacts

Boehringer Ingelheim Study Coordinator
study chair · Boehringer Ingelheim
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion